FR3054963B1 - Utilisation d'un inhibiteur de la synthese de novo des purines, dans le traitement du deficit en adenylosuccinate lyase - Google Patents

Utilisation d'un inhibiteur de la synthese de novo des purines, dans le traitement du deficit en adenylosuccinate lyase Download PDF

Info

Publication number
FR3054963B1
FR3054963B1 FR1657690A FR1657690A FR3054963B1 FR 3054963 B1 FR3054963 B1 FR 3054963B1 FR 1657690 A FR1657690 A FR 1657690A FR 1657690 A FR1657690 A FR 1657690A FR 3054963 B1 FR3054963 B1 FR 3054963B1
Authority
FR
France
Prior art keywords
purines
deficit
inhibitor
treatment
novo synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1657690A
Other languages
English (en)
Other versions
FR3054963A1 (fr
Inventor
Irene Ceballos-Picot
Laurence ROBEL
Pascale DE LONLAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ihu Imagine
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris 5 Rene Descartes
Original Assignee
Ihu Imagine
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris 5 Rene Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ihu Imagine, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris 5 Rene Descartes filed Critical Ihu Imagine
Priority to FR1657690A priority Critical patent/FR3054963B1/fr
Priority to EP17764875.5A priority patent/EP3496723A1/fr
Priority to CA3033446A priority patent/CA3033446A1/fr
Priority to US16/324,454 priority patent/US20190298722A1/en
Priority to PCT/FR2017/052213 priority patent/WO2018029430A1/fr
Publication of FR3054963A1 publication Critical patent/FR3054963A1/fr
Application granted granted Critical
Publication of FR3054963B1 publication Critical patent/FR3054963B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1657690A 2016-08-10 2016-08-10 Utilisation d'un inhibiteur de la synthese de novo des purines, dans le traitement du deficit en adenylosuccinate lyase Expired - Fee Related FR3054963B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR1657690A FR3054963B1 (fr) 2016-08-10 2016-08-10 Utilisation d'un inhibiteur de la synthese de novo des purines, dans le traitement du deficit en adenylosuccinate lyase
EP17764875.5A EP3496723A1 (fr) 2016-08-10 2017-08-08 Utilisation d'un inhibiteur de la synthese de novo des purines, dans le traitement du deficit en adenylosuccinate lyase
CA3033446A CA3033446A1 (fr) 2016-08-10 2017-08-08 Utilisation d'un inhibiteur de la synthese de novo des purines, dans le traitement du deficit en adenylosuccinate lyase
US16/324,454 US20190298722A1 (en) 2016-08-10 2017-08-08 Use of an inhibitor of the de novo synthesis of purines, in the treatment of adenylosuccinate lyase deficiency
PCT/FR2017/052213 WO2018029430A1 (fr) 2016-08-10 2017-08-08 Utilisation d'un inhibiteur de la synthese de novo des purines, dans le traitement du deficit en adenylosuccinate lyase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1657690A FR3054963B1 (fr) 2016-08-10 2016-08-10 Utilisation d'un inhibiteur de la synthese de novo des purines, dans le traitement du deficit en adenylosuccinate lyase
FR1657690 2016-08-10

Publications (2)

Publication Number Publication Date
FR3054963A1 FR3054963A1 (fr) 2018-02-16
FR3054963B1 true FR3054963B1 (fr) 2018-09-14

Family

ID=57860942

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1657690A Expired - Fee Related FR3054963B1 (fr) 2016-08-10 2016-08-10 Utilisation d'un inhibiteur de la synthese de novo des purines, dans le traitement du deficit en adenylosuccinate lyase

Country Status (5)

Country Link
US (1) US20190298722A1 (fr)
EP (1) EP3496723A1 (fr)
CA (1) CA3033446A1 (fr)
FR (1) FR3054963B1 (fr)
WO (1) WO2018029430A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018059214A1 (fr) * 2016-09-29 2018-04-05 广州君赫生物科技有限公司 Composés affectant la synthèse de saicar, et applications
US11517541B2 (en) 2017-04-20 2022-12-06 Geneheal Biotechnology Co., Ltd. Applications of spermidine and its derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014067038A1 (fr) * 2012-10-29 2014-05-08 广州百赫医疗信息科技有限公司 Point repère, préparation et méthode de traitement de carence en adsl chez l'être humain
WO2017033963A1 (fr) * 2015-08-26 2017-03-02 株式会社スタージェン Agent de renforcement de l'atp dans les cellules

Also Published As

Publication number Publication date
US20190298722A1 (en) 2019-10-03
FR3054963A1 (fr) 2018-02-16
EP3496723A1 (fr) 2019-06-19
CA3033446A1 (fr) 2018-02-15
WO2018029430A1 (fr) 2018-02-15

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
DK3334422T3 (da) Anvendelse af cannabidiolsyre i behandling af epilepsi
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
DK3562486T3 (da) Anvendelse af sublingual dexmedetomidin til behandling af agitation
MA42439A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
EA201790649A1 (ru) Бензилзамещенные индазолы в качестве ингибиторов bub 1
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA46836A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3609529T3 (da) Rna til behandling af autoimmune sygdomme
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3865484T3 (da) Pde9-hæmmer med imidazopyrazinon-rygrad til behandling af perifere sygdomme
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
DK3236983T3 (da) Hidtil ukendt pi3k-gamma-inhibitorpeptid til behandling af sygdomme i åndedrætssystemet
TWD183051S (zh) 淨水器
DK3452100T3 (da) FARMACEUTISKE BÆRERE INDEHOLDENDE miRNAer TIL ANVENDELSE I BEHANDLINGEN AF FIBROTISKE SYGDOMME FORÅRSAGET AF HYPERGLYKÆMI
MA41629A (fr) Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
DK3423060T3 (da) Imatinib til anvendelse til behandling af slagtilfælde
DK3406258T3 (da) Medikament til anvendelse til behandling af urinsyregigt
FR3054963B1 (fr) Utilisation d'un inhibiteur de la synthese de novo des purines, dans le traitement du deficit en adenylosuccinate lyase
DK3096775T3 (da) SOCS-mimetika til behandling af sygdomme
FR3000895B1 (fr) Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques
FR3046169B1 (fr) Utilisation de sels de dihydroisoquinolinium pour le traitement des matieres keratiniques, compositions et procedes de mise en oeuvre
FR3036946B3 (fr) Dispositif pour utilisation dentaire pour discriminer la couleur de dents

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180216

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

ST Notification of lapse

Effective date: 20210405